NCT07015346View on ClinicalTrials.gov

Adhesion and Safety of Rotigexole Compared to Neupro®

NANot yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

October 15, 2025

Study Completion Date

October 30, 2025

Conditions

Idiopathic Parkinson Disease

Interventions

DRUG

Rotigexole 8 mg

Rotigotine 8 mg

DRUG

Neupro ® 8 mg

Rotigotine 8 mg

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

MARC-CRO

UNKNOWN

lead

Eva Pharma

INDUSTRY